Evidence map›Paper›PMID 39326503›Full record

ArticleAntiviral research2024

Optimization of Bangladesh and Malaysian genotype recombinant reporter Nipah viruses for in vitro antiviral screening and in vivo disease modeling.

Michael K Lo, Shilpi Jain, Katherine A Davies, Teresa E Sorvillo, Stephen R Welch, JoAnn D Coleman-McCray, Payel Chatterjee, Anne L Hotard, Troy O'Neal, Mike Flint and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michael K LoCenters for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: mko2@cdc.gov.
Shilpi JainEmory National Primate Research Center, Emory Vaccine Center, Emory University, Atlanta, GA, USA.
Katherine A DaviesCenters for Disease Control and Prevention, Atlanta, GA, USA; U.S. Department of Agriculture, Agricultural Research Service, Zoonotic and Emerging Disease Research Unit, National Bio and Agro-Defense Facility, Manhattan, KS, USA.
Teresa E SorvilloCenters for Disease Control and Prevention, Atlanta, GA, USA.
Stephen R WelchCenters for Disease Control and Prevention, Atlanta, GA, USA.
JoAnn D Coleman-McCrayCenters for Disease Control and Prevention, Atlanta, GA, USA.
Payel ChatterjeeCenters for Disease Control and Prevention, Atlanta, GA, USA.
Anne L HotardCenters for Disease Control and Prevention, Atlanta, GA, USA.
Troy O'NealCenters for Disease Control and Prevention, Atlanta, GA, USA.
Mike FlintCenters for Disease Control and Prevention, Atlanta, GA, USA.
Huiwang AiUniversity of Virginia, School of Medicine, Charlottesville, VA, USA.
Cesar G AlbariñoCenters for Disease Control and Prevention, Atlanta, GA, USA.
Jessica R SpenglerCenters for Disease Control and Prevention, Atlanta, GA, USA.
Joel M MontgomeryCenters for Disease Control and Prevention, Atlanta, GA, USA.
Christina F SpiropoulouCenters for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: ccs8@cdc.gov.

Funding

Next-Generation ATP-Independent Luciferases, Luciferins, and Bioluminescent Calcium IndicatorsR01EB035430 · NIBIB · UNIVERSITY OF VIRGINIA · PI Huiwang Ai · 2024 to 2026
$1.4M
NIBIB NIH HHS R01 EB035430
6 · The paper itself

Abstract

Nipah virus (NiV) causes near-annual outbreaks of fatal encephalitis and respiratory disease in South Asia with a high mortality rate (∼70%). Since there are no approved therapeutics for NiV disease in humans, the WHO has designated NiV and henipaviral diseases priority pathogens for research and development. We generated a new recombinant green fluorescent reporter NiV of the circulating Bangladesh genotype (rNiV-B-ZsG) and optimized it alongside our previously generated Malaysian genotype reporter counterpart (rNiV-M-ZsG) for antiviral screening in primary-like human respiratory cell types. Validating our platform for rNiV-B-ZsG with a synthetic compound library directed against viral RNA-dependent RNA polymerases, we identified a hit compound and confirmed its sub-micromolar activity against wild-type NiV, green fluorescent reporter, and the newly constructed bioluminescent red fluorescent double reporter (rNiV-B-BREP) NiV. We furthermore demonstrated that rNiV-B-ZsG and rNiV-B-BREP viruses showed pathogenicity comparable to wild-type NiV-B in the Syrian golden hamster model of disease, supporting additional use of these tools for both pathogenesis and advanced pre-clinical studies in vivo.

Indexed as

Antiviral AgentsDisease Models, AnimalGenes, ReporterGenotypeHenipavirus InfectionsMesocricetusNipah VirusAnimalsBangladeshCell LineCricetinaeDrug Evaluation, PreclinicalGreen Fluorescent ProteinsHumansLuminescent ProteinsMalaysiaAntiviral AgentsGreen Fluorescent ProteinsLuminescent ProteinsAntiviral screeningBangladeshBioluminescent red proteinHenipavirusHSAEC1-KTMRC-5Nipah virusReporter virus assaySyrian golden hamsterZsGreen fluorescent protein

Identifiers

PMID39326503
PMCPMC11772256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.